Explore how we are focusing where we can have the greatest impact; in therapeutic areas where there are high unmet patient needs.
Imagine a world where disease doesn’t stop you living your life on your own terms. Where treatment happens with you, not to you. Where medicines reduce the burden of disease for people and society. At Novartis, our teams are more energized than ever to work together and with partners in industry and academia to turn scientific breakthroughs into medicines that change lives.
Together, let’s reimagine medicine to improve and extend people’s lives.
Cardiovascular, renal and metabolic
Transforming the treatment and healthcare system landscape using early interventions, pioneering treatments, and innovative partnerships to avoid preventable mortality from cardiovascular disease (CVD), the world’s biggest killer, and ease the burden for people living with rare and progressive kidney disease by extending dialysis-free life.
Immunology
Working to create a world where the millions of people with immunological conditions, and those who treat them, can live without compromise.
Neuroscience
Creating a transformational impact for people living with severe neurological conditions and their caregivers by discovering, developing and delivering innovative medicines that change the course of disease progression.
Oncology
Combining the power of science and empathy to unravel the inner workings of cancer and develop innovative therapies that restore hope to those with cancer and their loved ones.
Related links
Disease
To help people contending with serious diseases. People with serious diseases need breakthrough medicines to help them feel a restored sense of control, and possibility. Our disease area teams collaborate across scientific disciplines and organizations in pursuit of innovation to improve and extend people’s lives.
Pipeline
Benefiting from our continued focus on innovation. Novartis has one of the industry's most competitive pipelines.
Products
List of the treatments we currently offer via our Innovative Medicines Division.